Aluvia H-W-764

  • Email
  • Help
Name of the medicinal productAluvia
Opinion holderAbbVie Limited
Abbott House
Vanwall Business Park
Vanwall Road
Maidenhead
SL6 4UB
United Kingdom
Active substanceLopinavir / ritonavir
International non-proprietary name or common nameLopinavir / ritonavir
Pharmaco-therapeutic group

Antivirals for systemic use

ATC codeJ05AR10
Therapeutic indicationAluvia is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.

The choice of Aluvia to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1).
Orphan medicinal product designation dateNot applicable

Back to top

Document(s) Language Status First published Last updated Effective Date
Aluvia : Summary for the public (English only)   2010-01-29 2010-09-07  
Aluvia : All presentations (English only)   2010-01-29    
Aluvia : Scientific discussion (English only)   2010-01-29    
Aluvia : Procedural steps taken before scientific opinion (English only)   2010-01-29    
Aluvia : Procedural steps taken and scientific information after opinion (English only)   2010-01-29 2018-03-15  

Product Information* 20/07/2017 Aluvia-H-W-764-WS-1178

Back to top

Document(s) Language Status First published Last updated Effective Date
Aluvia : Product information (English only)   2010-01-29 2018-03-15  

Related links

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.